A view into Neurodegeneration and neurodegenerative diseases Bahareh Eftekharzadeh Laboratory of Dr. Xavier Salvatella SemesterI Crazy about Biomedicine.

Slides:



Advertisements
Similar presentations
Etiopathogenesis of Alzheimer's disease
Advertisements

ALZHEIMER’S DISEASE Erin Dancey. Overview Alzheimer’s is the most common cause of dementia in adult life and is associated with the selective damage of.
OXIDATIVE STRESS. INDUCTION OF OXIDATIVE STRESS Glutathione conjugation MalnutritionMutation Phagocytic activation Tissue damageSmoking.
Rapid detection of drugs for protein misfolding diseases. Alexey Krasnoslobodtsev, Department of Pharmaceutical Sciences, University of Nebraska Medical.
The following is an animation demonstrating the effects of prions on neuronal cells. Prions are misfolded proteins which provoke an array of neurodegenerative.
PHL 437/Pharmacogenomics Fourth Lecture (Parkinson’s disease) By Abdelkader Ashour, Ph.D. Phone:
Parkinson’s Disease Pathology 430/826 The Molecular Basis of Disease Neurological Genetics 9 th March 2015 Dr. John Rossiter
(Foundation Block) Dr. Ahmed Mujamammi Dr. Sumbul Fatma
Lewy Bodies in PD. Lewy Body Inclusions and the effect of coffee and decaffeinated extracts on Drosophila neuronal cultures.
Protein-Misfolding Diseases PHY6940 April 8 th 2009 Jessica Nasica.
What is Aging? Alzheimer’s Disease Parkinson’s Disease.
Alzheimer’s Disease By: Ryan Triplett. Alzheimer’s The deterioration of intellectual capabilities, memory, judgment, and personality to the extent that.
Proteins Dr. Sumbul Fatma Clinical Chemistry Unit
Chapter 21. Molecular Mechanisms of Neurological Disease Copyright © 2014 Elsevier Inc. All rights reserved.
Biology of Neurodegenerative Diseases BIOS E-108
Protein Misfolding: Therapeutic Implications
BIOCHEMISTRY DR AMENA RAHIM. Structure of Elastin It is a connective tissue protein Rubber like properties Elastin & glycoprotein microfibrils are present.
A carboxylated Zn-phthalocyanine inhibits the fibril formation of Alzheimer’s amyloid β peptide Atsushi Nagai Dept. Laboratory Medicine Shimane University.
Alzheimer Disease By Ashley Wallace. Facts Discovered by Alois Alzheimer in 1907Discovered by Alois Alzheimer in /3 or more of all diagnosed cases.
By Desmond Hanan THE NERVOUS SYSTEM. WHAT DOES IT DO? The nervous system is the part of the body that is in charge of data processing and controls an.
Α-synuclein, Lewy Bodies, Prions, and Parkinson’s Disease Cody McCullough & Sara Homsi BCM 465 April 19 th, 2010.
By : Amirah nu’aimi Sharifah Nurul Hanim TASK 2 – DISCUSS THE EXAMPLE OF PROTEIN FOLDING DISEASE BY STATING THE MECHANISM.
Simulations of Peptide Aggregation Joan-Emma Shea Department of Chemistry and Biochemistry The University of California, Santa Barbara.
Introduction Alzheimer’s disease (AD) is a neurodegenerative disease associated with brain shrinkage and the loss of neurons, particularly cholinergic.
PATHOLOGIC AGGREGATION OF THE BRAIN PROTEIN  -SYNUCLEIN CAUSES CELL DEATH IN PARKINSON AND ALZHEIMER DISEASE, Wenbo Zhou, PhD and Curt R. Freed, MD Division.
1 Alzheimer’s Disease & Acetylcholine Presentation by: Huy Nguyen Chemistry 12B Instructor: Dr. Adamczeski Fall-2006.
Aging Nervous System. Neurotrophic Factors Necessary for Maintenance of Neurons Neurotrophin function o Play role in development of NS o Interact with.
Protein Structure (Foundation Block) What are proteins? Four levels of structure (primary, secondary, tertiary, quaternary) Protein folding and stability.
Protein Structure (Foundation Block) What are proteins? Four levels of structure (primary, secondary, tertiary, quaternary) Protein folding and stability.
Protection of rat primary hippocampal cultures from Aβ cytotoxicity by pro-inflammatory molecules is mediated by astrocytes Neurobiology of disease, Vol.
Limitation of animal models in drug discovery and development Candice Tahimic, Ph.D. Hence, there is a need to use human cells to test the efficacy of.
Proteins Dr. Sumbul Fatma Clinical Chemistry Unit Department of Pathology Tel
Protein conformational disorders Amyloid Alice Skoumalová.
D E M E N T I A Q: What other types of dementia are there? Q: What other types of dementia are there? Q: Do they have the same pathophysiology as Alzeimer.
Bioinformatics: Practical Application of Simulation and Data Mining Protein Aggregation I Prof. Corey O’Hern Department of Mechanical Engineering & Materials.
Under the supervision of miklós jászberényi
Α-synuclein transgenic mouse models of Parkinson’s disease Michelle Maurer December 2015.
A NTIBODY -B ASED T HERAPEUTICS FOR T REATING A LZHEIMER ’ S AND P ARKINSON ’ S D ISEASES Taylor Brownlee Dr. Michael Sierks Chemical Engineering 2012.
Pathogenesis and pathology of parkinsonism
Diseases and Disorders of the Nervous System. schizophrenia Characterized by psychotic episodes involving hallucinations & delusions Genetic & environmental.
Protein Chemistry and Protein Engineering 서울대학교 화학생물공학부 백 승 렬.
Do Now 2/9/15 1.Describe possible causes for forgetting a memory. 2.Compare and contrast semantic and episodic memories.
Protein Related Diseases
Mechanism of Curcumin Inhibiting Amyloid-  Peptides Aggregation by Molecular Dynamics Simulations Zhenyu Qian, and Guanghong Wei State Key Laboratory.
“HEALTH IS THE BEST” In the name of God. WHAT IS IT? Parkinson's disease (PD) is a chronic and progressive movement disorder, meaning that symptoms.
Alzheimer Disease (Senile Dementia) Characterized by progressive memory loss, is increasingly common in developed countries as populations include more.
The ageing brain Volume reduction: begins around 50 with a loss of brain weight of around 2-3% per decade Changes in nerve cell numbers and size - various.
CLINICAL CORRELATIONS
Protein conformational disorders
Protein Folding Diseases
Title: Alzheimer’s disease and the social
CLINICAL CORRELATIONS
Protein conformational disorders
Neurodegeneration caused by prions. A
“The effects of chronic changes to the functioning of the nervous system due to interference to neurotransmitter function, illustrated by the role of Dopamine.
Q: How can we prevent or treat Alzheimer’s Disease?
Immunotherapeutic Approaches for Alzheimer’s Disease
Nat. Rev. Neurol. doi: /nrneurol
Nat. Rev. Neurol. doi: /nrneurol
Protein Misfolding, Amyloid Formation, and Neurodegeneration
CLINICAL CORRELATIONS
Parkinson's Disease Neuron
Drugs for Degenerative Diseases of the Nervous System
Who looks like they might have Alzheimer’s Disease?
Mechanisms Underlying Inflammation in Neurodegeneration
Protein Misfolded Oligomers: Experimental Approaches, Mechanism of Formation, and Structure-Toxicity Relationships  Francesco Bemporad, Fabrizio Chiti 
Targets of thiazolidinedione (TZD) drugs in Alzheimer’s disease.
-supported study By Dr. Chao Peng
Volume 5, Issue 5, Pages (May 1997)
A Proposed Mechanism for Neurodegeneration in Movement Disorders Characterized by Metal Dyshomeostasis and Oxidative Stress  Benjamin Guy Trist, Dominic.
Presentation transcript:

A view into Neurodegeneration and neurodegenerative diseases Bahareh Eftekharzadeh Laboratory of Dr. Xavier Salvatella SemesterI Crazy about Biomedicine 2013

Brain With Alzheimer's Disease Crazy about Biomedicine 2013

How the Brain and Nerve Cells Change During Alzheimer's Disease Medical illustration showing how the brain and nerve cells change during Alzheimer's Crazy about Biomedicine 2013

Plaques and Tangles in Alzheimer`s disease Crazy about Biomedicine 2013

How the Brain and Nerve Cells Change During Alzheimer's Disease? Crazy about Biomedicine 2013

Brain With Parkinson's Disease Substantia Nigra: substantia nigra appear darker than neighboring areas due to high levels of melanin in dopaminergic neurons and Parkinson's disease is characterized by the death of dopaminergic neurons in the substantia nigra.

Crazy about Biomedicine 2013 How the Brain and Nerve Cells Change During Parkinson's Disease Medical illustration showing how the brain and nerve cells change during Parkinson's Comparison between a normal brain and a diseased brain Alpha-synuclein aggregates are responsible for neuronal dead in brain cells

Crazy about Biomedicine 2013 An example of tremor in Parkinson's Disease Medical illustration showing how the brain and nerve cells are affected during Parkinson's Substantia nigra is an important player in brain function, in particular, in eye movement, motor planning, reward-seeking, learning.

Cerebral aggregates in neurodegenerative diseases are toxic. signature of Alzheimer’s disease: 1.Extracellular amyloid plaques 2.Intracytoplasmic neurofibrillary tangles Intracytoplasmic aggregates are typically present in the neurons of people affected by Parkinson’s disease and amyotrophic lateral sclerosis. Intranuclear inclusions of huntingtin are observed in Huntington’s disease patients and extracellular prion amyloid plaques that are located in different brain regions are present in some cases of transmissible spongiform encephalopathy. Crazy about Biomedicine 2013

In spite of the different protein compositions, the ultrastructure of these deposits seems to be similar and composed mainly of a network of fibrillar polymers. Crazy about Biomedicine 2013

Now the question is: how these aggregates form in the cells and what initiates the aggregation formation????

Introduction in protein structure equilibrium Crazy about Biomedicine 2013

Schematic representation of the pathway leading to protein misfolding and aggregation 1.The natively folded protein, normally produced in diverse cell types, adopts a random coil or α - helical conformation. 2. In the elderly brain, the first pathological step would be the formation of a misfolded intermediate that exposed to the aqueous environment hydrophobic fragments that are normally buried inside the protein. 3. This intermediate has a high tendency to aggregate and become stabilized, in a rate- limiting process, by the formation of an oligomeric β -sheet structure, which by incorporation of additional monomers gives rise to protofibrils and finally to cross- β amyloid-like fibrils.

Crazy about Biomedicine 2013 Schematic representation of different therapeutic strategies to arrest protein misfolding and aggregation 1.Stabilization of the folding of the native protein. 1. Inhibition and reversal of protein misfolding by compounds that can specifically destabilize β - sheet structures. 1.Competitive inhibition of protein oligomerization by compounds that bind to the monomeric protein. 1.Competitive inhibition of aggregation by molecules that bind to aggregated β -sheets and block further incorporation of monomers. 2.Increased clearance of the misfolded/aggregated protein by compounds that boost clearance mechanisms or decrease the stability of protein aggregates.

Crazy about Biomedicine 2013 The benefits of animal models for studying the diseases Different approaches to study Neurodegeneration: How can we generate the transgenic animals?

Crazy about Biomedicine 2013 Different approaches to study Neurodegeneration: How transgenic animals can be studied in an example?

Crazy about Biomedicine 2013 Different approaches to study Neurodegeneration: How transgenic animals can be studied in an example?

Crazy about Biomedicine 2013 Different approaches to study Neurodegeneration: 2. Biochemical approaches to study neurodegeneration

What is Alzheimer’s diseases??? Crazy about Biomedicine 2013

Discussion How do you see the future of the neurodegenerative disease’s research? Which approaches will answer more questions? What is the role of Pharmaceutical companies in developing new drugs? Who plays more important role in solving the questions in Alzheimr’s and Parkinson’s diseases? The scientists or industry? What is your next step, if you would like to stay in this field of research? …